Gil Yosipovitch, M.D. Joins Trevi Therapeutics Clinical Advisory Board
Noted pruritus key opinion leader is Director of the Temple Itch Center at the Temple University School of Medicine
New Haven, CT, October 1, 2014 - Trevi Therapeutics, Inc. (“Trevi”), a late-stage development biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced that Gil Yosipovitch, M.D. has joined its Clinical Advisory Board. In that role, Dr. Yosipovitch, Professor and Chair of The Department of Dermatology and Director of the Temple Itch Center at the Temple University School of Medicine in Philadelphia, Pennsylvania, will work closely with Trevi’s Co-founders, Jennifer Good and Thomas Sciascia, M.D., on the Company’s development programs. Dr. Yosipovitch will join Dr. Jeffrey Bernhard, M.D., also a noted dermatologist and key opinion leader in pruritus, on the Company’s Clinical Advisory Board.
Thomas Sciascia, M.D., Trevi’s Chief Medical Officer, said, “Dr. Yosipovitch is one of the world’s experts in itch, and we are grateful to have his experience and counsel as we plan and conduct the pivotal clinical trials for Nalbuphine ER in uremic pruritus and prurigo nodularis. Itch is becoming increasingly recognized as an important unmet medical need, and we look forward to partnering with one of the innovators in this disease as we execute on our development programs for Nalbuphine ER.”
Dr. Yosipovitch said, “I look forward to working with the Trevi team to continue the development of Nalbuphine ER for the serious unmet medical needs in chronic pruritus. Given my previous research and clinical experience in itch, the dual mechanism of action for Nalbuphine ER is an exciting potential treatment pathway for these otherwise refractory types of pruritus, and the Company has already generated compelling clinical data to support this experience.”
Dr. Yosipovitch’s research studies focus on neurophysiology of itch and scratch, brain imaging of itch, skin innervation and sensory testing and developing and testing anti-pruritic drugs. He has published more than 250 articles in books and peer-reviewed journals. He is the founder and past president of the International Forum for The Study of Itch (IFSI), which is a multidisciplinary international association of clinicians and researchers dedicated to improving the understanding of itch. Dr. Yosipovitch has been awarded several prestigious awards for his research.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a late-stage development biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with increased mortality. Prurigo nodularis is a skin disease characterized by severely pruritic nodules on the skin. There are no approved therapies in the US or EU for either disease.
Nalbuphine ER is an oral extended release opioid with a unique opioid receptor dual agonist/antagonist mechanism of action, which has shown efficacy in addressing pruritus in both animal studies and human clinical trials. Because of Nalbuphine ER’s dual mechanism of action, the company believes it can have broad utility in treating chronic pruritus. Founded in 2011, Trevi is headquartered in New Haven, CT.
For additional information, visit www.trevitherapeutics.com.
# # #
Media contact: Laura Brophy, (203) 331-7618, email@example.com